All In Biotech

Drug Trial Radar · NCT06293651

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

an Open-Label, Phase 1/2a, First-in-Human Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

125

Planned (sponsor's estimate)

Start

Apr 18, 2024

Primary completion

Jan 2026

Study completion Oct 2029

Sponsor

Lead sponsor
Dong-A ST Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors.

Conditions

  • Locally Advanced or Metastatic Solid Tumors

Interventions

  • DA-4505Drug

    Phase 1a: Dose escalation Phase 1b: OBD and MTD Phase 2a: RP2D

  • DA-4505 + PembrolizumabDrug

    Phase 1a/b: OBD, MTD of DA-4505 + 200mg of Pembrolizumab Phase 2a: RP2D of DA-4505 + 200mg of Pembrolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of adverse events (AEs) meeting protocol-defined dose-limiting toxicity(DLT) criteriaTime frame: Cycle 1(21 days) in dose escalation
  2. PK parameters for DA-4505 (Peak Plasma Concentration (Cmax))Time frame: Day 1 and 2 of first 2 cycles (every 21 days)
  3. PK parameters for DA-4505 (Area Under the Curve (AUC))Time frame: Day 1 and 2 of first 2 cycles (every 21 days)
  4. PK parameters for DA-4505 (half-life (t1/2))Time frame: Day 1 and 2 of first 2 cycles (every 21 days)
  5. Response per revised "Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1)Time frame: approximately 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.